Navigation Links
NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
Date:9/21/2007

SAN CARLOS, Calif., Sept. 21 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX) announced today that it has completed enrollment in study C119, a second Phase 3 clinical trial of its lead product candidate NGX-4010 for the treatment of painful HIV-distal sensory polyneuropathy (HIV-DSP). NGX-4010 is a dermal patch designed to manage peripheral neuropathic pain. Previously completed Phase 3 trials demonstrated that a single, 30- or 60-minute treatment with NGX-4010 applied directly to the site of pain may provide pain relief for up to three months. C119 is a randomized, double-blind, controlled study that has enrolled over 480 patients at study sites in the United States, the United Kingdom, Australia and Canada.

"We believe that completion of enrollment in our C119 study marks a significant milestone in our NGX-4010 development program in HIV-DSP. We are currently in the follow-up phase of the study and expect to be able to provide top-line results near the end of the first quarter of 2008," commented Dr. Jeffery Tobias, Chief Medical Officer. "HIV-DSP is an important and underserved problem in patients with HIV/AIDS. There are currently no approved therapies for this indication. With the completion of enrollment in study C119, we are moving closer to our goal of providing an effective treatment for this patient population."

The study protocol for study C119 evaluates the effect of a single, 30- or 60-minute treatment with NGX-4010 or a low-concentration control patch applied directly to the patient's site of pain. NGX-4010 is administered by a physician during an in-office procedure. After 30 or 60 minutes, the study patch is removed and the patient's response to treatment is evaluated during the su
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
2. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
3. Celsion Completes Enrollment in Phase I Liver Cancer Study
4. LANI completes Phase I in Japan and to commence Phase I in UK
5. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
8. MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy
9. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... SAN DIEGO , Oct. 1, 2014   ... today the appointment of J. Patrick Ravenel ... years of enterprise software and systems experience and a ... Fortune 500 companies. "Patrick has been ... class software and systems and is known industry-wide for ...
(Date:10/1/2014)...  SI-BONE, Inc., a medical device company that pioneered the ... invasive surgical (MIS) device indicated for fusion for certain disorders ... its European operations with the formation of a GmbH and ... Manager, Germany.  Mr. Schaber will join former Kyphon colleague ... , Middle East and Asia ...
(Date:10/1/2014)... LAUSANNE , Switzerland , October ... European leader in Clinical Genomics and Next Generation Sequencing ... Solution allowing clinicians to run full cystic fibrosis analysis ... covers the identification and characterisation of all types of ... analytical performance. Until now, it has not ...
Breaking Medicine Technology:Cypher Genomics Appoints J. Patrick Ravenel Chief Technology Officer 2SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 2SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 3SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 4Sophia Genetics Launches Full CFTR Analysis in Single Clinical Grade NGS Experiment 2
(Date:10/1/2014)... Despite a policy focus on expanding access ... vulnerable population continues to have significant dental disease. ... of the American Dental Association , researchers from ... School of Dental Medicine report on the first ... care provided by caregivers to adults with developmental ...
(Date:10/1/2014)... Insuranceragents.info has released a new blog ... plan for vulnerable family members. , Life insurance plans ... in the family should always carry a life insurance ... the rest of the family. , Clients can ... more from temporary coverage or from a permanent policy. ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Phoseon Technology, ... , continues to expand the business worldwide. This rapid ... with additional capacity for manufacturing efforts. The company has ... last five years and expects this growth to continue ... curing technology gains worldwide adoption. , “We are ...
(Date:10/1/2014)... A new genetic finding from Duke Medicine suggests that ... depression might also be hard-wired to gain weight when ... disease. , An estimated 13 percent of people, all ... and knowing this could help them reduce heart disease ... and stress management. , "Genetic susceptibility, psychosocial stress and ...
(Date:10/1/2014)... 2014 Diet Doc understands that many of ... weight and their dieting attempts could be easily sabotaged by ... hormone diet treatments into their programs as a way ... fast and effective weight loss results, it also allows patients ... to maintain their weight for the future. , Earlier versions ...
Breaking Medicine News(10 mins):Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4
... offers Barry McMillen - Nicotine Cessation Expert and ... ... Using tobacco isn,t just a,habit; it,s an addiction. Hazelden has ... 50 years. The same principles,of the Hazelden treatment experience help tobacco ...
... University Hospitals Case Medical Center finds that Deep ... Tourette Syndrome (TS). This first-of-its-kind study of five ... tic frequency and severity in some people who ... is a neurobehavioral disorder characterized by sudden, repetitive ...
... sent to kill them, study finds , , MONDAY, Nov. ... of molecular weapons that helps make community-associated methicillin-resistant ... work must be done, the study "provides a partial ... causing infection and gives a starting point in the ...
... contribute to high mercury,levels in fish Americans consume, ... dental mercury air,emissions may be more than five times ... The U.S. House,Subcommittee on Domestic Policy of the ... Wednesday, Nov. 14, to discuss FDA,s,responsibility to evaluate the ...
... 12 Indiana Gov. Mitch,Daniels joined executives from ... to announce the company,s plans to build the ... Indiana, filling a growing,nationwide demand for lower-cost medicines. ... 2009, will cover an area equivalent to,six and ...
... AdCare Health,Systems, Inc. (Amex: ADK ) announced ... results on Wednesday, November 14th, 2007. In conjunction,with ... call on November,15th, at 4:15 EST. The telephone ... unable to participate at that time, playback is,available ...
Cached Medicine News:Health News:Quit Smoking Tips For The Great American Smokeout Day - November 15 2Health News:University Hospitals Case Medical Center finds new treatment holds promise for Tourette syndrome 2Health News:University Hospitals Case Medical Center finds new treatment holds promise for Tourette syndrome 3Health News:Key to MRSA Virulence in Community Discovered 2Health News:Key to MRSA Virulence in Community Discovered 3Health News:Environmental Impacts of Dental Mercury Focus of U.S. House Oversight Hearing Wednesday 2Health News:Medco to Build World's Largest, Most Advanced Automated Pharmacy in Central Indiana 2Health News:Medco to Build World's Largest, Most Advanced Automated Pharmacy in Central Indiana 3Health News:Medco to Build World's Largest, Most Advanced Automated Pharmacy in Central Indiana 4Health News:Medco to Build World's Largest, Most Advanced Automated Pharmacy in Central Indiana 5Health News:AdCare Health Systems, Inc. Announces 2007 Third Quarter Earnings Release and Conference Call Schedule 2
Improve your refractive outcome, with AXIS II precision biometry A-scan. Biometry clinically proven as accurate as partial coherence interferometry while not limited by dense media....
... with graphic display and IOL power ... combination units include firmware module with ... II formulas. Audible tones increase in ... visual axis. Constant tone when alignment ...
... ("I-cubed") is an exceptionally high resolution, ... oscilloscope (static deflection) display. This provides ... low cost video monitors. Vitreous structures ... cells, as well as tumor vascularity ...
... sensitive B-scan system which quickly identifies ocular asymmetry. ... eyes differ by more than 0.3 mm, a ... The B5500 enables quick and easy identification of ... or inserting shells under the lids. The B5500 ...
Medicine Products: